Loading organizations...
§ Private Profile · American Fork, UT, USA
Clinical-stage biopharmaceutical company developing AI-driven oral small-molecule therapies for obesity and diabetes.
Founded in 2021 by David Bearss and Hariprasad Vankayalapati, Biolexis Therapeutics is a clinical-stage biopharmaceutical company based in Lehi, Utah, that utilizes artificial intelligence to discover small-molecule therapies for metabolic, oncological, and neurodegenerative diseases. The organization leverages its proprietary MolecuLern process to advance a pipeline of forty discovery programs, with ten currently in IND enabling stages. Its primary clinical focus centers on oral drugs targeting obesity and diabetes, specifically combining GLP-1 receptor agonism with AMPK activation to create muscle-sparing treatments. Operating with fewer than twenty-five employees, the enterprise has successfully raised over twelve million dollars across four funding rounds, including a ten million dollar Series A led by Clarke Capital Partners. The firm recently announced its upcoming presentation at the prestigious JP Morgan Healthcare Conference and currently holds a portfolio of over one hundred patents.
Biolexis Therapeutics has raised $10.0M across 1 funding round.
Biolexis Therapeutics has raised $10.0M in total across 1 funding round.
Biolexis Therapeutics has raised $10.0M in total across 1 funding round.
Biolexis Therapeutics's investors include James Clarke.
Biolexis Therapeutics has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series A in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 6, 2023 | $10M Series A | James Clarke, Wincanton | — | Announced |